Weighed down by bad reviews, 'Morbius' opens with $39.1M

Sony Pictures’ Marvel adaptation “Morbius” landed with dismal reviews but still managed to debut with $39.1 million in ticket sales, according to studio estimates Sunday

Film Review - Morbius
Film Review - Morbius

Sony Pictures' Marvel adaptation “Morbius" landed with dismal reviews but still managed to debut with $39.1 million in ticket sales, according to studio estimates Sunday.

That was enough to easily hand “Morbius,” starring Jared Leto as a vampire-transforming biochemist, the top spot at the box office — even though it was an uncharacteristically low debut for a Marvel movie. Sony's last movie to launch a Marvel character, 2018's “Venom,” opened in 2018 with double the ticket sales.

But “Morbius" also drew unusually bad reviews for a Marvel release. On Rotten Tomatoes, it sits with easily the worst score for a Marvel film at 17% fresh. “Venom” (30%) wasn't a hit with critics, either. But given that forecasts had ranged closer to a $50 million opening weekend for “Morbius,” the poor word-of-mouth and worse reviews likely cut into its receipts.

“This is a weak opening by Marvel’s exceptional standard for launching a new superhero series," said David A. Gross, who runs the consulting firm Franchise Entertainment Research. “The weekend figure is well below average for a Marvel first episode, and below average compared with a DC Comics new series, as well.”

Still, “Morbius," delayed several times by the pandemic, was budgeted somewhat modestly for a comic-book film, costing $75 million to produce. Audiences also gave it a low grade — C+ from CinemaScore — though moviegoers still seemed to like it more than critics. The audience score from Rotten Tomatoes for the Daniel Espinosa-directed film is 69% fresh.

Overseas, “Morbius” grossed $44.9 million over the weekend, for an $84 million global haul.

Still, it will be hard for “Morbius” to get anywhere close to Sony's recent Marvel successes. The last two were box-office hits: “Spider-Man: No Way Home” has grossed nearly $1.9 billion worldwide, while last year's “Venom 2” took in $502 million globally.

Last week’s top film, the Sandra Bullock-Channing Tatum rom-com adventure “The Lost City,” slid to second place with $14.8 million in its second week. With a two-week total of $54.6 million, “The Lost City” is performing much better than other recent entries in the genre.

Following the Academy Awards, Apple put best picture-winner “CODA” into more than 500 theaters. The film, which debuted on Apple TV+ last August, became the first movie from a streaming service ever to take Hollywood's top honor. Apple didn't share ticket-sales figures Sunday, making “CODA” the first best-picture winner without any recorded U.S. box office.

Also working against “Morbius”: The box office is getting busier. While no new wide releases went up against the Sony release this weekend, the coming weeks bring the releases of “Sonic the Hedgehog 2,” “Ambulance” and “Fantastic Beasts: The Secret of Dumbledore.” The next Marvel movie, “Doctor Strange in the Multiverse of Madness,” comes from the Walt Disney Co. on May 6.

Estimated ticket sales for Friday through Sunday at U.S. and Canadian theaters, according to Comscore. Final domestic figures will be released Monday.

1. "Morbius," $39.1 million.

2. “The Lost City,” $14.8 million.

3. “The Batman,” $10.8 million.

4. “Uncharted,” $3.6 million.

5. “Jujutsu Kaisen 0,” $1.9 million.

6. “RRR,” $1.6 million.

7. “Spider-Man: No Way Home,” $1.4 million.

8. “Dog,” $1.3 million.

9. “X,” $1 million.

10. “Everything Everywhere All at Once,” $1 million.

___

Follow AP Film Writer Jake Coyle on Twitter at: http://twitter.com

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in